• Publications
  • Influence
Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy Volunteers
Two 14‐day, placebo‐controlled, double‐blind studies evaluated the fasting pharmacokinetics, safety, and tolerability of aripiprazole, a new antipsychotic, in healthy male subjects. In Study 1, 37Expand
  • 147
  • 12
Cilostazol Pharmacokinetics after Single and Multiple Oral Doses in Healthy Males and Patients with Intermittent Claudication Resulting from Peripheral Arterial Disease
ObjectiveTo study the pharmacokinetics of cilostazol following single oral administration of 50 to 200mg in healthy young males, and after repeated oral administration of 100mg every 12 hours toExpand
  • 65
  • 10
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study
This 24-week, open-label, Phase Ib, parallel-arm, multiple-dose trial assessed the pharmacokinetics, safety and tolerability of a once-monthly injection of aripiprazole (aripiprazole once-monthly) inExpand
  • 61
  • 8
Background: ACU-4429 is a first in class small-molecule visual cycle modulator that inhibits the isomerase complex and, in mouse models of retinal degeneration, prevents the accumulation of A2E. TheExpand
  • 75
  • 6
Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single‐Dose Studies in Healthy Subjects
Two single‐center, double‐blind, randomized, placebo‐controlled, sequentially enrolled studies were conducted. In study 1, 8 subjects (6 active/2 placebo) received 60‐, 90‐, 120‐, 180‐, or 240‐mgExpand
  • 72
  • 6
Pharmacokinetics of Aripiprazole and Concomitant Lithium and Valproate
The objective of this study was to assess the pharmacokinetics of the antipsychotic aripiprazole when coadministered with lithium or valproate. Two open‐label, sequential treatment design studiesExpand
  • 67
  • 4
Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole in Healthy Subjects and in Patients with Schizophrenia
AbstractBackground and objective: Patients with schizophrenia or bipolar disorder who are experiencing acute behavioural emergencies often require intramuscular injection of antipsychotics for rapidExpand
  • 26
  • 4
Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine
The objective of this study was to assess the pharmacokinetics of aripiprazole when coadministered with carbamazepine using an open-label sequential treatment design in patients with schizophrenia orExpand
  • 41
  • 3
Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole
AbstractBackground and objectives: Two studies were conducted to investigate whether the pharmacokinetics of the atypical antipsychotic aripiprazole were altered in individuals with hepatic or renalExpand
  • 32
  • 3
Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole
Abstract Objective: Safety and tolerability assessment of initiating treatment with a once monthly long-acting injectable form of aripiprazole (aripiprazole once monthly) in patients stabilized onExpand
  • 22
  • 3